VTRS · 10-Q · 2026Q2

Viatris Inc

Filed 2026-08-06 · Healthcare · View original filing on EDGAR

Ranked Events

• Other Income (Expense), NetImportance 77 · Surprise 82
  Second-quarter 2026 other income was $50.4 million, compared with $333.5 million of other expense in the prior-year quarter, a favorable change of $383.9 million. The improvement primarily reflected a $56.3 million…
• Acquisition / Partnership / DivestitureImportance 71 · Surprise 60
  Viatris sold all of its preferred shares in Biocon Biologics under agreements signed in December 2025 for total consideration of $815.0 million, consisting of $400.0 million in cash and $415.0 million of newly issued…
• Income Tax Rate ChangesImportance 65 · Surprise 82
  Viatris recorded a $54.8 million income tax provision in the second quarter of 2026, compared with a $212.5 million tax benefit in the prior-year quarter, a $267.3 million unfavorable change. The 2026 provision was…
• Accrued Legal and RegulatoryImportance 64 · Surprise 42
  Viatris had approximately $453 million accrued for legal contingencies at June 30, 2026, covering disputes, governmental and regulatory inquiries, investigations, tax proceedings, and litigation in the United States…
• Interest Rate and Refinancing ExposureImportance 64 · Surprise 42
  During the six months ended June 30, 2026, Viatris repaid approximately $1.675 billion of 3.950% Senior Notes at maturity and issued approximately $752.8 million of 4.250% Euro Senior Notes due 2033. The Company also…
• Headcount / RestructuringImportance 64 · Surprise 42
  Viatris expects its 2026 enterprise-wide strategic review restructuring program to reduce its global workforce by up to approximately 10% and to be implemented primarily over three years. The program is expected to…
• Distribution ChannelsImportance 60 · Surprise 40
  Greater China constant-currency net sales increased 17% in the first six months of 2026 and 16% in the second quarter. Growth was broad-based across multiple channels, specifically including e-commerce and retail.…
• Revenue Performance and MixImportance 59 · Surprise 32
  Second-quarter 2026 total revenues increased 5% year over year to $3.76 billion from $3.58 billion, while constant-currency revenues rose 4% to $3.71 billion. Greater China net sales increased 21% to $713.8 million, or…
• Geographic Market CommentaryImportance 54 · Surprise 40
  Greater China was the strongest growth market, with constant-currency net sales up 17% in the first six months and 16% in the second quarter, driven by broad-based growth across multiple channels. Developed Markets…
• Research and Development ExpenseImportance 54 · Surprise 40
  Second-quarter 2026 R&D expense increased $29.5 million, or 13%, to $248.3 million from $218.8 million. Six-month R&D expense increased $56.1 million, or 13%, to $496.9 million from $440.8 million. The increase in both…
• Liquidity and Debt PositionImportance 49 · Surprise 6
  Viatris reported $886.5 million of cash and cash equivalents at June 30, 2026 and $770.1 million of operating cash flow for the six months then ended. The Company expects available cash, operating cash generation, and…
• Gross Margin DriversImportance 49 · Surprise 32
  Second-quarter 2026 gross profit increased $123.6 million to $1.46 billion, and reported gross margin expanded to 39% from 37%, primarily because of product mix. Six-month gross profit increased $119.6 million to $2.61…
• Regulatory RiskImportance 47 · Surprise 60
  A February 2026 fire at Viatris’ oral solid-dose manufacturing facility in Nashik, India temporarily suspended manufacturing. After a May 2026 FDA inspection produced Form 483 observations, Viatris began a…
• Manufacturing and Supply DisruptionsImportance 47 · Surprise 60
  An FDA warning letter and import alert affecting Viatris’ Indore, India facility continue to restrict 11 products from entering the U.S., with negative effects also reported in the Emerging Markets ARV business and…
• Product Launch and TransitionImportance 46 · Surprise 42
  Viatris’ constant-currency net sales increased 3% in the first six months of 2026, supported by approximately $171.8 million of new product sales, primarily in Developed Markets, and $60.7 million of net base business…
• Operating Cash Flow TrendsImportance 42 · Surprise 14
  Net cash provided by operating activities was $770.1 million for the six months ended June 30, 2026, up $14.9 million from $755.2 million in the comparable 2025 period. The increase was principally due to higher…
• Capital Return ProgramImportance 38 · Surprise 24
  Viatris’ board-authorized share repurchase program permits up to $2.0 billion of common-stock repurchases and has no expiration date. During the three and six months ended June 30, 2026, the company repurchased…
• Competition and Pricing PressureImportance 37 · Surprise 42
  Viatris operates in a highly competitive pharmaceutical market where additional generic entrants generally reduce affected-product volume and pricing, especially after periods of market exclusivity. Generic entry for…
• Capital Expenditure PlanImportance 24 · Surprise 14
  Viatris spent approximately $92.7 million on capital expenditures for equipment and facilities during the six months ended June 30, 2026, compared with $95.5 million in the prior-year period. Net cash from investing…

Revenue by Product (in millions)

Revenue by Geography (in millions)